Eisai has struggled since falling off the patent cliff in 2010, when its blockbuster Alzheimer's med Aricept lost patent protection and sales took a hit. The company is looking to new meds to add salve to the wound, and a better-than-expected launch for its cancer hopeful Lenvima could be exactly what the doctor ordered.
An analysis by AdverseEvents shows the new generation of obesity meds are holding their own, safety-wise. Still, postmarketing data flag some serious cardiovascular and neuropsychiatric side effects that are worth monitoring, the healthcare informatics firm says.
Eisai has been whittling down its U.S. workforce as part of broader cost-cutting moves in the face of a tough patent cliff go. Now the Japanese drugmaker will trim another 135 people from its payroll with the sale of a manufacturing facility in North Carolina to drug development partner Biogen.
Dieting and exercise to lose weight is more effective when done with support--and weight-loss drugmakers have taken that to heart in marketing their treatments. But according to a recent Journal of Public Policy & Marketing article, lifestyle support isn't enough. Drugmakers may want to look to their advertising pitches, too.
Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.
It's been a hard fall off the patent cliff for Eisai, but after 5 long years, the company says it sees its operating profit climbing in its next fiscal year.
Japan's Eisai, which is trying to cut costs worldwide, says it will produce more of its active pharmaceutical ingredients (APIs) at its facilities in India. The company merged two units in India in preparation. It also intends to try to sell more generic drugs.
Beginning in a year or two, Eisai plans to make major active pharmaceutical ingredients for generics at its Elmed Eisai state-of-the-art plants in India and import them to Japan, part of broader recent restructuring efforts by the company to trim costs.
Eisai said it and Glenmark reached a settlement of the Japan drugmaker's U.S. suit for patent infringement of its Banzel (rufinamide) epilepsy drug.
Eisai and Nihon Medi-Physics plan to work together on one of Japan's three major dementia types, termed "dementia with Lewy bodies," meaning abnormal massing of protein inside nerve cells. The research is part of a broad cascade of efforts around the globe into diagnostics and treatments for dementia-related studies.